To amend the Controlled Substances Act to permanently schedule the class of 2-benzylbenzimidazole-opioids known as nitazenes, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
Permanently schedules nitazenes and related 2-benzylbenzimidazole opioids as Schedule I substances under the Controlled Substances Act.
Who Benefits and How
Law-enforcement and public-health officials could gain stronger tools to control the spread of nitazene analogs in the illicit drug supply.
Who Bears the Burden and How
Manufacturers, distributors, researchers, and traffickers dealing with the covered substances would face stricter Schedule I restrictions and enforcement risk.
Key Provisions
- Finds that nitazenes pose serious overdose and public health risks.
- Adds a class-wide Schedule I listing for 2-benzylbenzimidazole opioids and deems previously temporary listings permanent.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Permanently schedules nitazenes and related 2-benzylbenzimidazole opioids as Schedule I substances under the Controlled Substances Act.
Key Policy Areas
Criminal Justice, Healthcare
Primary Purpose
Permanently schedules nitazenes and related 2-benzylbenzimidazole opioids as Schedule I substances under the Controlled Substances Act.
Policy Domains
Main Provisions
Identified Gains
Contextual inference, no direct clause citation- Public-health and law-enforcement stakeholders combating synthetic opioid proliferation
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Entities handling covered nitazene substances under stricter Schedule I controls
Contextual inference, no direct clause citation
Sponsors
Legislative Progress
IntroducedMr. McCormick (for himself, Mr. Gallego, Mr. Ricketts, Mrs. Shaheen, …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Manufacturers, distributors, and traffickers dealing in covered nitazene substances
Public-health and law-enforcement efforts addressing nitazene proliferation
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology